How to Buy Barinthus Biotherapeutics Stock
Barinthus Biotherapeutics PLC
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
Barinthus Biotherapeutics stock last closed at $1.03, down 0.49% from the previous day, and has decreased 57.47% in one year. It has overperformed other stocks in the Biotechnology industry by 0.24 percentage points. Barinthus Biotherapeutics stock is currently +27.97% from its 52-week low of $0.80, and -75.35% from its 52-week high of $4.16.
As of Mar 25, 2025, there are 40.34M shares of BRNS outstanding. The market value of BRNS is $41.35M. In the last 24 hours, 5073 BRNS shares were traded.
How to Buy Barinthus Biotherapeutics Stock
Wondering how to invest in Barinthus Biotherapeutics stock? Here's how.
- Figure out where to buy Barinthus Biotherapeutics stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Barinthus Biotherapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your investment account: Select your payment method and add your info.
- Analyze Barinthus Biotherapeutics stock: The Barinthus Biotherapeutics ticker symbol is BRNS. Is Barinthus Biotherapeutics stock a good investment? Should you buy shares of BRNS? How do BRNS's underlying business fundamentals look? Do top analysts think Barinthus Biotherapeutics is a good buy? Why has BRNS's stock price moved recently? (Hint: Our stock research tools can help you understand if BRNS is a good stock to buy).
- Execute your BRNS buy order: Decide if you will purchase BRNS shares at the current market price or use a limit order to buy BRNS shares at a specific price.
- Keep tabs on your BRNS position: Create a watchlist to keep track of your position in Barinthus Biotherapeutics shares.
Step 1: Figure out where to buy Barinthus Biotherapeutics stock
You need an online brokerage account in order to access the NASDAQ market and buy BRNS shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Tech to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the best brokerage, the next step is to fill out some personal information so you are able to invest in BRNS stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new brokerage account.
- Send your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have opened your account on the best stock app, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details depositing money into your brokerage account.
Step 4: Analyze Barinthus Biotherapeutics stock
After you have selected the best place to buy Barinthus Biotherapeutics stock, it's critical to evaluate their stock prior to investing, so you actually understand the risk and opportunity.
Barinthus Biotherapeutics Metrics
Barinthus Biotherapeutics Fundamentals
WallStreetZen was created to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on BRNS's stock page.
How is BRNS stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge BRNS's intrinsic value.
Using relative valuations metrics:
- BRNS may be undervalued based on its P/B ratio of 0.32x, relative to Biotechnology industry P/B ratio of 4.62x
You can access additional valuation research on BRNS's stock here.
BRNS Financial Health Summary
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the BRNS balance sheet.
- BRNS has $112.40M in cash and short term investments. This is enough to cover its annual cash burn of $29.83M.
- There are more short-term assets than short-term liabilities on the BRNS balance sheet.
- Total BRNS debt is lower than 5 years ago, relative to shareholder equity.
- BRNS has a low debt to equity ratio of 0.23.
- BRNS has cash burn of 29832000. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
- BRNS profit margin has gone up by 87.38 percentage points in the past year, but the company is still unprofitable.
Do analysts think it's a good time to buy Barinthus Biotherapeutics stock
Out of 1 sell side analysts who monitor BRNS, the consensus analyst rating on BRNS is a Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are saying on the Barinthus Biotherapeutics stock forecast page.
Metrics for Advanced BRNS Traders
BRNS Revenue
Last year, BRNS revenue was $14.97M. Over the past five year, BRNS's revenue has increased by 16.94% per year. This was slower than the Biotechnology industry average of 46.11%.
Dive into BRNS's earnings and revenue performance here.
Latest Insiders Trades at BRNS
In the last 12 months, executives and large shareholders at BRNS have not bought or sold any shares.
Dig into more about who owns BRNS stock here.
Does BRNS provide a stable income stream?
No, Barinthus Biotherapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about BRNS?
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your BRNS buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine for most investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount limit, place a limit order.
Click the Open button and eToro will execute your order.
If you need additional help with buying stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your BRNS position
Now that you own some BRNS stock, you'll want to keep up with your new investment.
Make a watchlist to keep tabs on your BRNS stock.
BRNS Feed
How to Buy Stock in Barinthus Biotherapeutics
To reiterate, here are the 6 steps for buying Barinthus Biotherapeutics stock:
- Figure out where to buy Barinthus Biotherapeutics stock
- Open your brokerage account
- Fund your investment account
- Analyze Barinthus Biotherapeutics stock
- Execute your BRNS buy order
- Keep tabs on your BRNS position
If you need a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Barinthus Biotherapeutics, add BRNS to your watchlist by clicking the button below.
Other Articles You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.